Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.

Paola Fioretto Stephano Del PratoJohn B BuseRonald GoldenbergFrancesco GiorginoDaniel ReynerAnna Maria LangkildeC David SjöströmPeter Sartipynull null

Published in: Diabetes, obesity & metabolism (2018)

The findings of this study (NCT02413398, clinicaltrials.gov) support the positive benefit/risk profile of dapagliflozin for the treatment of patients with T2D and CKD 3A.

Keyphrases

chronic kidney disease
end stage renal disease
high intensity
combination therapy